The money will pay for efforts to prevent and treat opioid addiction, or fund services that help people in recovery.
The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.
ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.
Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Public health experts have concerns about the opioid reversal agent Opvee. But the company that makes it, Indivior, has found ...
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Hosted on MSN6d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Verywell Health on MSN9d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionFact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback